ACTC - Advanced Cell Technology | Stock Discussion Forums

SiliconInvestor

register

Sponsor

register

Biotech / Medical | ACTC - Advanced Cell Technology

Previous 10 | Next 10

From: Savant	1/23/2012 9:55:41 AM
	of 92

ACT Announces Europe's First Human Embryonic Stem Cell Transplant in Patient with Stargardt's Disease Moorfields Eye Hospital in London Initiates Clinical Trial Using hESC-derived RPE cells MARLBOROUGH, Mass., Jan 23, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the first patient in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, Jan. 20, at the Moorfields Eye Hospital in London by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The patient successfully underwent the procedure without any complications. ACT and Moorfields Eye Hospital received clearance in September from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) to begin this trial in Europe. "Our clinical trial program for hESC-derived RPE cells has taken another critical step as we move forward with treating patients at Moorfields Eye Hospital," said Gary Rabin, chairman and chief executive officer of ACT. "The treatment of the first patient in Europe is tangible evidence that stem cell research and development of cell therapies is making progress. It is a milestone for scientists, stem cell advocates and patients hoping for cures as well as much as it is one for ACT. Stargardt's macular dystrophy affects up to 100,000 patients in Europe and North America, and causes progressive vision loss often ending with blindness. We are honored to be working with Professor Bainbridge at Moorfields Eye Hospital, and are very pleased with the smooth progress of the trial thus far." Professor James Bainbridge, the study's principal investigator, said, "The patient, who is severely sight-impaired, underwent transplantation of fully differentiated retinal pigment epithelial (RPE) cells derived from human embryonic stem cells. There were no complications, and the patient has tolerated the surgical procedure well. We will be regularly monitoring the safety and tolerability of the transplanted cells. While this is primarily a safety trial, we will have the opportunity to image engraftment of RPE cells non-invasively and to assess any changes in sight. We are very excited to be working with ACT on the first human embryonic stem cell trial in Europe. Stargardt's macular dystrophy is a serious and progressive disease that usually starts between the age of 10 and 20 years. It includes degeneration of RPE cells in the macula at the center of the retina, the region specialized for high acuity vision. With the loss of RPE cells in the macula comes the eventual loss of light-sensitive photoreceptor cells, leading to blindness at the prime of life. We hope that transplantation of healthy RPE cells might also help in other significant degenerative eye diseases affecting the retina for which there are no effective treatment options -- particularly dry age-related macular degeneration which is the leading cause of blindness in Europe." The Phase 1/2 trial will involve 12 patients, with cohorts of 3 patients each in an ascending dosage format and is similar in design to the FDA-approved U.S. trial that was initiated in July 2011. The open-label study is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with Stargardt's macular dystrophy at 12 months, the study's primary endpoint. "Stem cells provide the possibility of providing new treatment strategies for currently incurable retinal degenerative diseases," said Robert Lanza, M.D., chief scientific officer of ACT. "Although these initial studies are designed to determine the safety and tolerability of hESC-derived RPE, we eventually hope to treat patients earlier in the course of the disease, further increasing the likelihood the new cells will rescue photoreceptors and prevent visual loss. We recently initiated two clinical trials in the U.S. and are very pleased to be starting the first clinical trial in Europe. To-date, our preclinical and clinical data relating to the safety and effectiveness of this approach is very encouraging. We look forward to working with Professor Bainbridge and Moorfields Eye Hospital to obtain additional clinical data and to enroll further patients in this trial. As a scientist, it is satisfying to see years of benchside research finally moving into the clinic. We believe RPE is just the first of many different vital differentiated cell types that may help patients suffering from a wide spectrum of eye disorders caused by conditions ranging from diabetes to vascular and autoimmune diseases." In August 2011, the National Institute of Health Research (NIHR) announced the award of Biomedical Research Centre (BRC) for Ophthalmology at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The award provides 26.5 million pounds Sterling over five years to translate lab-based discoveries into new cutting edge treatments, technologies, diagnostics and other interventions in clinical settings. About hESC-RPE Cells The retinal pigment epithelium (RPE) is a highly specialized tissue located between the choroids and the neural retina. RPE cells support, protect and provide nutrition for the light-sensitive photoreceptors. Human embryonic stem cells differentiate into any cell type, including RPE cells, -- and have a similar expression of RPE-specific genes compared to human RPE cells and demonstrate the full transition from the hESC state. About SMD, Dry AMD and Degenerative Diseases of the Retina Stargardt's macular dystrophy (SMD) is one of the most common forms of macular degeneration in the world. Stargardt's causes progressive vision loss, usually starting between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium or RPE cell layer. Degenerative diseases of the retina are among the most common causes of untreatable blindness in the world. As many as 30 million people in the United States and Europe suffer from macular degeneration, which represents a $25-30 billion worldwide market that has yet to be effectively addressed. Approximately 10% of people ages 66 to 74 will have symptoms of macular degeneration, the vast majority suffering from the "dry" form of AMD -- which is currently untreatable. The prevalence increases to 30% in patients 75 to 85 years of age. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company's clinical trials will be successful. SOURCE: Advanced Cell Technology, Inc. Investors: CEOcast, Inc. James Young, 212-732-4300 or Press: Russo Partners Martina Schwarzkopf, Ph.D., 212-845-4292 or 347-591-8785 martina.schwarzkopf@russopartnersllc.com or Tony Russo, Ph.D., 212-845-4251 tony.russo@russopartnersllc.com or ACT Corporate Communications Bill Douglass, 646-450-3615 or Business Development: Advanced Cell Technology Matthew Vincent, Ph.D., 508-756-1212 x324 mvincent@advancedcell.com

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	1/24/2012 12:38:13 AM
	of 92

WSJ BLOG/Health: Some Promising Findings on Embryonic Stem Cells Last Update: 1/23/2012 5:02:33 PM (This story has been posted on The Wall Street Journal Online's Health Blog at blogs.wsj.com By Katherine Hobson Very early results fromresearch into embryonic stem cell treatments suggest that the therapy was safe in use against macular degeneration, a major cause of blindness. The findings, though preliminary, are the first published results involving embryonic stem cells in human patients. In the report, which covered two patients followed over four months, the patients reported some visual improvement that may -- or may not -- spring from the treatment. But much more research needs to be done before the therapy can be deemed a success. Writing in the Lancet, researchers from biotech firm Advanced Cell Technology and the University of California, Los Angeles reported turning human embryonic stem cells into the key cells lost in macular degeneration, known as retinal pigment epithelial cells. Two legally blind patients then had these cells surgically implanted into one eye. The patients -- one with dry age-related macular degeneration and one with a related condition called Stargardt's macular dystrophy -- showed no signs of the safety problems that have been a worry with embryonic-stem-cell-derived therapy. "There were no tumors, and there was no immune rejection" after patients were tapered off of immunosuppressive drugs, said Steven Schwartz, an author of the study and chief of the retina division at UCLA's Jules Stein Eye Institute. The patients also reported visual changes that "could be a sign of improvement," said Dr. Schwartz. For instance, the Stargardt's patient, in her 50s, went from discerning only hand motions to being able to count fingers. She also reported improved color vision. But Dr. Schwartz cautioned that the improved vision reported by the patients might be chalked up to the placebo effect, the surgery, the immunosuppressive drugs or "all of the above," he said. "Objectively, there is no consensus in how to measure vision in low-vision patients," he said. The clinical trials studying the drugs in the two different forms of macular degeneration will eventually include 24 patients at different centers, followed intensively for a year and then tracked for years afterwards, said Robert Lanza, an author of the study and chief scientific officer at Advanced Cell Technology, which is developing the therapy and funded the research. He said if studies in these patients with advanced disease pan out, eventually the aim is to target patients at much earlier stages of macular degeneration. Dr. Lanza said even limited data from two patients is "of great value to the scientific community" because of the safety concerns that have surrounded embryonic stem cell research. The research has also been controversial for ethical reasons, given that the extraction of stem cells from a human embryo results in the destruction of the embryo, which some critics say amounts to taking human life. Stem cells can develop into any kind of tissue. The research is difficult and resource-heavy. Another company, Geron Corp. said in November it would exit the entire field of embryonic stem cell research, citing financial constraints. As part of that move, it halted a small trial of embryonic stem cells in people with spinal-cord injuries. That study had been the first trial of the technology to be approved in humans. Dr. Lanza said this work also "paves the way" for working with so-called induced pluripotent stem cells, adults cells taken from the patient and reprogrammed back to an earlier state. Those have the benefit of avoiding the ethical issues surrounding embryonic cells as well as the prospect of rejection by the body. Image of embryonic stem cells via NIH Image Bank -For continuously updated news from The Wall Street Journal, see WSJ.com at wsj.com.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	1/25/2012 9:20:21 AM
	of 92

ACT Announces that Additional Patient with Stargardt's Disease Has Undergone Embryonic Stem Cell Transplantation at UCLA's Jules Stein Eye Institute MARLBOROUGH, Mass., Jan 25, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the dosing of an additional patient in its Phase 1/2 trial for Stargardt's macular dystrophy using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patient was treated on Tuesday (Jan. 24) by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA's Jules Stein Eye Institute. The patient successfully underwent the outpatient transplantation surgery and is recovering uneventfully. "This is the fourth patient worldwide treated with ACT's hESC-derived RPE cells," said Gary Rabin, chairman and chief executive officer of ACT. "We are pleased to be on schedule with our clinical programs to test the safety and tolerability of ACT's stem cell-derived RPE cells. We are working with the best ophthalmology institutes to evaluate the capacity of our cell therapy which may have the ability to treat a variety of devastating diseases." The clinical trial will enroll 12 patients each, with cohorts of three patients each in an ascending dosage format. It is a prospective, open-label study, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with Stargardt's macular dystrophy at 12 months, the study's primary endpoint. The patient, a 47-year-old male, was treated with the smallest dose of 50,000 cells. The hESC-derived RPE cells are currently also in Phase 1/2 for dry age-related macular degeneration. Preliminary results for the first two patients in each of the Phase 1/2 clinical trials were recently reported in The Lancet. A third Phase1/2 trial for Stargardt's macular dystrophy was recently initiated at the Moorfields Eye Hospital in London, treating the first patient on Jan. 20. Stargardt's Macular Dystrophy (SMD) is one of the most common forms of macular degeneration in the world. SMD causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium or RPE cell layer. Further information about patient eligibility for the Stargardt's macular dystrophy study is also available on clinicaltrials.gov About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company's clinical trials will be successful. SOURCE: Advanced Cell Technology, Inc. Investors: CEOcast, Inc. James Young, 212-732-4300 or Press: ACT Corporate Communications Bill Douglass, 646-450-3615 or Russo Partners Martina Schwarzkopf, Ph.D., 212-845-4292

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: FUBHO	2/2/2012 10:03:10 AM
	1 Recommendation of 92

NEWARK, Calif., Feb. 2, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq: STEM - News) today announced that the U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase I/II clinical trial of the Company's proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD), the most common form of AMD. AMD is the leading cause of vision loss and blindness in people over 55 years of age, and approximately 30 million people worldwide are afflicted with the disease. There are no approved treatments for dry AMD. "With the approval of this trial, we have accomplished something truly unique in the stem cell field, which is the extension of clinical testing of our proprietary human neural stem cell platform to all three elements of the central nervous system: the brain, spinal cord and eye," said Martin McGlynn, President and CEO of StemCells, Inc. "The preclinical data supporting our IND is particularly compelling and we look forward to getting this trial underway." The Phase I/II trial will evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. The trial will be an open-label, dose-escalation study, and is expected to enroll a total of 16 patients. The HuCNS-SC cells will be administered by a single injection into the space beneath the retina. Patients' vision will be evaluated using conventional methods of ophthalmological assessment at predetermined intervals over a one-year period. Patients will then be followed for an additional four years in a separate observational study. Preclinical data submitted as part of the Company's Investigative New Drug application demonstrated that HuCNS-SC cells protect host photoreceptors and preserve vision in a well-established animal model of retinal disease that is relevant to dry AMD. HuCNS-SC transplants significantly protect against the degeneration of photoreceptors, the key cells of the eye involved in vision. Moreover, the number of cone photoreceptors, which are responsible for central vision, remain constant over an extended period, consistent with the sustained visual acuity and light sensitivity observed. In humans, degeneration of the cone photoreceptors account for the unique pattern of visual loss in dry AMD. A summary of the Company's preclinical data was published in the February issue of the international peer-reviewed European Journal of Neuroscience, and is available online at onlinelibrary.wiley.com "We have published the preclinical evidence demonstrating that our human neural stem cells might offer a safe, effective and simple approach to treating AMD and other retinal diseases," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "Our approach is to provide durable protection of photoreceptors, thereby preserving vision, as opposed to approaches that aim to replace photoreceptors or the retinal pigmented epithelial cells. Furthermore, our preclinical data supports our hypothesis that we can achieve clinical benefit with a single transplant in AMD patients."

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	3/1/2012 5:40:54 PM
	of 92

Advanced Cell Technology Announces 2011 Financial Results MARLBOROUGH, Mass., Mar 01, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT", OTCBB: ACTC), a leader in the field of regenerative medicine, today announced year-end results for the year ended December 31, 2011. The Company utilized $13.6 million in cash for operations during the year, compared to $8.8 million in the year-earlier period. The increase in cash utilization resulted primarily from ACT's ongoing clinical activities in the US and Europe. ACT ended the year with cash and cash equivalents of $13.1 million, compared to $15.9 million in cash and cash equivalents in the year-earlier period. Some of the 2011 highlights included: -- FDA and MHRA clearance for clinical trials using human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) to treat dry age-related macular degeneration (AMD) and Stargardt's Macular Dystrophy (SMD) in the US and Europe -- Leading ocular medical institutions such as UCLA's Jules Stein Eye Institute and the Wills Eye Institute in Philadelphia chosen as sites for the Company's Phase I/II clinical trials -- Commencement and dosing of patients in the first ever clinical trials using (hESC)-derived RPE cells to treat dry AMD and SMD -- First patients in SMD and dry AMD clinical trials pass Data & Safety Monitoring Board (DMSB) review. Company approved to treat next patients -- Global settlement agreement reached with debenture holders releasing the Company from significant contingent liabilities -- Strengthened Board of Directors through the appointments of industry experts Gregory D. Perry, Zohar Loshitzer, and Dr. Robert Langer -- Secured patent covering the single-blastomere technology allowing cultivation of human embryonic stem cells without embryo destruction -- Company receives exclusive license for hemangioblast technology in North America and first patent for generating hemangioblast cells to treat vascular and hematopoietic disorders -- EU Orphan Medicinal Product Designation for hESC-derived RPE cells for treatment of Stargardt's Disease -- Issued broad patent for hESC-derived RPE cells in China -- Collaboration with Roslin Cells for storage and distribution of embryonic stem cells using ACT's Blastomere Technology "2011 was a very important and successful year for ACT as we began our Phase 1/2 trials for the treatment of macular degeneration," said Gary Rabin, chairman and CEO of ACT. "We are very excited about the preliminary Phase 1/2 clinical data from our dry-AMD and Stargardt's disease trials, which were published in The Lancet earlier this year. The data demonstrated the safety of ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells for the treatment of both diseases. The vision of both patients appears to have improved after transplantation, and no adverse safety issues have been observed. We look forward to validating these early findings as we expand these clinical activities throughout this year. Additionally, we made significant progress in advancing our scientific platform, expanding our board of directors and management team and strengthening our balance sheet." The Company also announced today that it expects to shortly file a preliminary proxy statement with the Securities and Exchange Commission in which it will seek shareholder approval for a reverse split of between 1-for 20 and 1-for 80 shares. The Company is pursuing the reverse split for the sole purpose of meeting the requirements necessary for a listing on the Nasdaq Global Market. The Company believes that a listing on a national change will allow it to expand its shareholder base and improve the marketability of its common stock by attracting a broader range of investors. Conference Call The Company will hold a conference call at 9:00 a.m. EST tomorrow, during which it will discuss 2011 results and provide an update on clinical activities. Interested parties should dial (888)264-3177 followed by the reference conference ID number: 57426004. The call will be available live and for replay by webcast at: us.meeting-stream.com About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company's clinical trials will be successful. SOURCE: Advanced Cell Technology, Inc. Investors: CEOcast, Inc. James Young, 212-732-4300 or Press: ACT Corporate Communications Bill Douglass, 646-450-3615 or Russo Partners Martina Schwarzkopf, Ph.D., 212-845-4292

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	3/15/2012 8:24:38 PM
	of 92

On March 14, 2012, Advanced Cell Technology, Inc. (the "Company") issued a press release regarding a proposed reverse stock split and other matters to be acted upon at the Company's annual meeting of shareholders to be held on April 26, 2012. A copy of the Company's press release is attached hereto as Exhibit 99.1. MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that on Monday, March 12 it filed with the Securities and Exchange Commission a proxy statement containing a shareholder proposal for a reverse split of its common stock. The annual meeting of stockholders will be held on Thursday, April 26, at the Hyatt Regency Suites, Palm Springs, 285 N. Palm Canyon Dr., Palm Springs, Calif., 92262, on Thursday, April 26, 2012, at 9 a.m. PDT, to consider the following proposals: election of five directors, ratifying the appointment of the company’s public accounting firm, and a proposal to effect a reverse stock split of the company’s common stock, at a ratio between one-for-twenty and one-for-eighty, and to reduce the number of authorized shares of the company’s common stock in the same proportion as the reverse split, with the exact ratio to be determined by the board of directors. “This reverse stock split, which should better align the company’s capital structure with its stage of development, and an accompanying Nasdaq listing application, will represent a significant step toward creating long-term shareholder value and building ACT into a world-class player in the regenerative medicine space,” said Gary Rabin, chairman and CEO of ACT. “I hope that our stockholders understand how important it is to vote ‘For’ the reverse stock split. A Nasdaq listing will enable us to significantly broaden our shareholder base and attract institutional ownership, a process that can build on itself to position the company on very firm financial footing over the long term.” Stockholders who have questions on how to vote or need assistance voting their shares should contact the company’s proxy solicitor InvestorCom, Inc. toll-free at (877) 972-0090. Further Information ACT has filed with the Securities and Exchange Commission (the “SEC”) and will furnish to stockholders of record on the record date for the annual meeting a definitive proxy statement in connection with the reverse stock split and other matters to be acted upon at the annual meeting. The company, Mr. Rabin and certain of its directors, executive officers and other members of management may, under SEC rules, be deemed “participants” in the solicitation of proxies from the company’s stockholders with respect to the reverse stock split and the other matters to be acted upon at the annual meeting. INVESTORS AND STOCKHOLDERS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED REVERSE STOCK SPLIT AND OTHER IMPORTANT INFORMATION INCLUDING THOSE PERSONS WHO MAY BE DEEMED “PARTICIPANTS” IN THE SOLICITATION. Investors and stockholders may obtain a free copy of the definitive proxy statement, and other documents filed by us with the SEC, including the preliminary proxy statement, at the SEC’s web site at http://www.sec.gov. Free copies of the definitive proxy statement, and the Company’s other filings with the SEC may also be obtained from the Company by directing a request to Advanced Cell Technology, Inc., 33 Locke Drive, Marlborough, Massachusetts 01752, Attention: Secretary. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	3/15/2012 8:27:54 PM
	of 92

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company’s chairman and CEO, Gary Rabin, will be presenting at Roth Capital Partners’ 24th Annual ROTH Conference, March 11-14. Mr. Rabin’s presentation will take place on Wednesday, March 14, at 12:00PM PDT at the Ritz Carlton Laguna Niguel, Salon 2, in Dana Point, Calif. The presentation slide deck will be available on the Conference Presentations section of the ACT website and the webcast of the presentation will be available via the following link: http://wsw.com/webcast/roth26/actc.ob/. Roth Capital Partners plans to host more than 400 growth companies at its 24th annual investment conference, March 11-14, including more than 130 healthcare companies in the biotechnology, healthcare services, medical device, and pharmaceutical sectors. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	3/15/2012 8:34:29 PM
	of 92

8-Mar-2012 Unregistered Sale of Equity Securities, Other Events, Financial St Item 3.02. Unregistered Sales of Equity Securities. The information set forth under Item 8.01 in this current report on Form 8-K is incorporated by reference into this Item 3.02. The shares that we agreed to issue to Cranshire will be issued in reliance upon the exemption from registration set forth in Section 3(a)(10) of the Securities Act of 1933, as amended. Item 8.01. Other Events. On March 8, 2012, the United States District Court for the Southern District of New York Court approved the exchange agreement entered into on February 24, 2012 between Advanced Cell Technology, Inc. and Cranshire Master Fund, Ltd (the "Exchange Agreement") in connection with the lawsuit entitled Capital Master Fund, Ltd. v. Advanced Cell Technology, Inc., Case No. 11 CIV 8755 (S.D.N.Y. filed December 1, 2011). As previously disclosed in our recent Form 10-K, pursuant to the Exchange Agreement, we have agreed, in exchange for dismissal of the pending lawsuit with prejudice and a mutual release of all claims, to issue 4,941,605 shares of our common stock to Cranshire and to release the escrow proceeds from the sale of the 10,730,265 shares of our common stock issued to Cranshire pursuant to the order of the Court entered on December 15, 2011. The shares will be delivered to Cranshire in accordance with the terms of the Exchange Agreement and the escrow proceeds will be released to Cranshire immediately, the releases will become effective and the action will be dismissed with prejudice. The foregoing description of the Exchange Agreement is qualified in its entirety by reference to the full text of the Exchange Agreement attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

Previous 10 | Next 10

Copyright/IP Policy

Copyright © 1995-2013 Knight Sac Media. All rights reserved.